A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Dirix, Radka Obermannová, Jonathan Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua K. Sabari, Sonya C. Chapman, Wei Zhang, Boris Calderón, Daniel A. Peterson
Topics & Concepts
DurvalumabTremelimumabMedicineInternal medicinePharmacokineticsCancerGastroenterologyResponse Evaluation Criteria in Solid TumorsOncologyChemotherapyPhases of clinical researchImmunotherapyNivolumabIpilimumabImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersLung Cancer Research Studies